A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK-2262167 hydrate | GSK-2262167 is a potent S1P3-sparing and S1P1 agonist and has a potent activity is in a collagen-induced arthritis model as efficacious as fingolimod and shows excellent pharmacokinetic properties preclinically. Uses: Arthritis. Synonyms: GSK-2262167 sodium; GSK 2262167 sodium; GSK2262167 sodium; sodium 3-(6-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydroisoquinolin-2(1H)-yl)propanoate. Grade: ≥98%. CAS No. 1458576-13-0. Molecular formula: C25H28N4O5. Mole weight: 464.51. |  |
| GSK-2262167 sodium | This molecular is a potent S1P3-sparing and S1P1 agonist. Meanwhile GSK-2262167 has a potent activity is in a collagen-induced arthritis model as efficacious as fingolimod and shows excellent pharmacokinetic properties preclinically. Uses: Arthritis. Synonyms: GSK-2262167 sodium; GSK 2262167 sodium; GSK2262167 sodium; sodium 3-(6-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydroisoquinolin-2(1H)-yl)propanoate,1165924-28-6 (free acid); 458576-13-0 (hydrate). Grade: 98%. CAS No. 1165923-54-5. Molecular formula: C25H25N4NaO4. Mole weight: 468.49. | |
| GSK2269557 | GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asthma. Uses: Gsk2269557 is an effective pi3k inhibitor that could be used as against inflammatory and some autoimmune diseases. Synonyms: CHEMBL2216859; GSK2269557 (free base); GSK2269557; GSK-2269557; GSK 2269557; Nemiralisib; 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole; 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole. Grade: 95%. CAS No. 1254036-71-9. Molecular formula: C26H28N6O. Mole weight: 440.54. | |
| GSK-2269557 HCl salt | GSK-2269557 is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by GlaxoSmithKline. GSK-2269557 is highly selective for PI3Kδ over the closely related isoforms and is active in a animal model of Th2-driven lung inflammation. Treatment for Asthma and Chronic obstructive pulmonary disease(COPD) is in clinical trials Phase II. Uses: Asthma; chronic obstructive pulmonary disease. Synonyms: GSK-2269557 HCl salt; GSK 2269557 HCl salt; GSK2269557 HCl salt; 6-(1H-indol-4-yl)?-4-[5-[[4-(1-methylethyl)?-1-piperazinyl]?methyl]?-2-oxazolyl]?-1H-indazole, monohydrochloride; 1254036-71-9(free base). Grade: 98%. CAS No. 1254036-77-5. Molecular formula: C26H28N6O; HCl. Mole weight: 477.01. | |
| GSK2292767 | GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials. GSK2292767 is highly selective for PI3Kδ over the closely related isoforms and is really active in the animal model of Th2-driven lung inflammation. Uses: Asthma and copd. Synonyms: GSK2292767; GSK-2292767; GSK 2292767. N-[5-[4-[5-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide; SCHEMBL173490; ZINC95938263; KB-78330; 1254036-66-2; Methanesulfonamide,N-[5-[4-[5-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]. Grade: 98%. CAS No. 1254036-66-2. Molecular formula: C24H28N6O5S. Mole weight: 512.58. | |
| GSK232 | GSK232, a highly selective, cellularly penetrant inhibitor of CECR2, has excellent physicochemical properties. Synonyms: (S)-N-(4-chloro-3-((3-cyclopropylpyrrolidin-1-yl)sulfonyl)phenyl)-2-(5-methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)acetamide. CAS No. 2702984-69-6. Molecular formula: C21H27ClN6O3S. Mole weight: 479.00. | |
| GSK2330672 | GSK-2330672, an ASBT inhibitor, has been developed for the treatment of type 2 diabetes and is currently under Phase II trail against primary biliary cirrhosis and type 2 diabetes. IC50: 42 ± 3 nM. Uses: Gsk-2330672 is an asbt inhibitor that has been developed for the treatment of type 2 diabetes and is currently under phase ii trail against primary biliary cirrhosis and type 2 diabetes. Synonyms: CHEMBL2387408; UNII-386012Z45S; GSK2330672; GSK-2330672; SCHEMBL2586025; CZGVOBIGEBDYTP-VSGBNLITSA-N. Grade: 98%. CAS No. 1345982-69-5. Molecular formula: C28H38N2O7S. Mole weight: 546.68. | |
| GSK2332255B | GSK2332255B is a potent and selective antagonist of TRPC3 and TRPC6 with IC50s of 5 and 4 nM for rat TRPC3 and rat TRPC6, respectively. It exhibits ≥100-fold selectivity for TRPC3/6 over other calcium-permeable channels. Synonyms: (5-chloro-2-((6-fluorobenzo[d][1,3]dioxol-5-yl)amino)thiazol-4-yl)(2,3-dimethylpiperidin-1-yl)methanone; Methanone, [5-chloro-2-[(6-fluoro-1,3-benzodioxol-5-yl)amino]-4-thiazolyl](2,3-dimethyl-1-piperidinyl)-; GSK-255B. Grade: ≥90%. CAS No. 1366233-41-1. Molecular formula: C18H19ClFN3O3S. Mole weight: 411.88. | |
| GSK2334470 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| GSK2334470 | GSK2334470 is a potent 3-phosphoinositide-dependent protein kinase (PDK1) inhibitor (IC50 ~ 10 nM), which does not suppress the activity of 93 other protein kinases including 13 AGC-kinases most related to PDK1 at 500-fold higher concentrations. GSK2334470 also inhibited T-loop phosphorylation and activation of Akt. GSK2334470 will be a useful tool for delineating the roles of PDK1 in biological processes. Synonyms: GSK2334470; GSK2334470; GSK2334470. Grade: 0.98. CAS No. 1227911-45-6. Molecular formula: C25H34N8O. Mole weight: 462.602. | |
| GSK2334470 | GSK2334470 is a highly specific and potent inhibitor of PDK1 with an IC50 of 10 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1227911-45-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-14981. |  |
| GSK239512 | GSK239512 is a potent and brain penetrated H 3 receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 720691-69-0. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-106000. | |
| GSK-239512 | GSK-239512 is a histamine H3 receptor antagonist. In Jun 2015, Phase-II for Schizophrenia in USA was discontinued. Phase II clinical trilas for the treatment of Multiple sclerosis are on-going. Uses: Multiple sclerosis. Synonyms: GSK-239512; GSK239512; GSK 239512; 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-2-Pyrrolidinone. Grade: 98%. CAS No. 720691-69-0. Molecular formula: C23H27N3O2. Mole weight: 377.48. | |
| GSK-25 | GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor with an IC50 of 7 nM. GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50 = 398 nM, p70S6K: IC50 = 1 μM). Synonyms: GSK25; GSK 25; 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-6-Methyl-. Grade: 99%. CAS No. 874119-56-9. Molecular formula: C24H16Cl2F2N6O. Mole weight: 513.33. | |
| GSK251 | GSK251 is a potent and selective PI3Kδ inhibitor. Synonyms: GSK-251; GSK 251. Grade: 98% by HPLC. CAS No. 2125968-05-8. Molecular formula: C29H37FN6O4S. Mole weight: 584.7. | |
| GSK256066 | GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7. Synonyms: GSK256066; GSK 256066; GSK-256066. Grade: >98%. CAS No. 801312-28-7. Molecular formula: C27H26N4O5S. Mole weight: 518.58. | |
| GSK256066 2,2,2-trifluoroacetic acid | GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7. Synonyms: GSK-256066; GSK 256066. Grade: >98%. CAS No. 1415560-64-3. Molecular formula: C29H27F3N4O7S. Mole weight: 632.61. | |
| GSK256073 | GSK256073 is a potent, selective and orally active G-protein coupled receptor 109A (GPR109A) agonist and a long-lasting and non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) full agonist with a pEC50 of 7.5 for human HCA2. It acutely improves glucose homeostasis by inhibiting lipid breakdown and has the potential to study type 2 diabetes mellitus (T2DM) and dyslipidemia. Synonyms: 8-Chloro-3-pentyl-1H-purine-2,6(3H,7H)-dione; 1H-Purine-2,6-dione, 8-chloro-3,9-dihydro-3-pentyl-; 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione; 8-Chloro-6-hydroxy-3-pentyl-3,9-dihydro-2H-purin-2-one. Grade: ≥95%. CAS No. 862892-90-8. Molecular formula: C10H13ClN4O2. Mole weight: 256.69. | |
| GSK256073 | GSK256073 Inhibitor. Uses: Scientific use. Product Category: T15432. CAS No. 862892-90-8. |  |
| GSK256073 | GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia[1][2]. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2. Uses: Scientific research. Group: Signaling pathways. CAS No. 862892-90-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-119222. | |
| GSK256471 | This active molecular is a selective and potent NK(3) antagonist. It has a high affinity for recombinant human (pK(I) value 8.9) and native guinea pig (pK(I) value 8.4) tachykinin NK(3) receptors. In the near future, GSK256471 may be potentially very useful in the treatment of schizophrenia. Uses: Treatment of schizophrenia. Synonyms: GSK256471; GSK-256471; GSK 256471. N-[(S)-cyclopropyl(phenyl)methyl]-3-[[methyl(methylsulfonyl)amino]methyl]-2-phenylquinoline-4-carboxamide. Grade: 98%. CAS No. 1133706-08-7. Molecular formula: C29H29N3O3S. Mole weight: 499.63. | |
| GSK2578215A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK2578215A | Potent leucine-rich repeat kinase 2 (LRRK2) inhibitor (IC50 values are 8.9 and 10.1nm respectively for LRRK2[G2019S] mutant and wild-type LRRK2 respectively). Displays selectivity for LRRK2 against a panel of 460 other kinases. Blocks Ser910 and Ser935 phosphorylation in vitro and in peripheral tissues in vivo. Brain penetrant. Group: Biochemicals. Alternative Names: 5-(2-Fluoro-4-pyridinyl)-2-(phenylm ethoxy)-N-3-pyridinylbenzamide. Grades: Highly Purified. CAS No. 1285515-21-0. Pack Sizes: 10mg, 25mg. US Biological Life Sciences. |  Worldwide |
| GSK2578215A | GSK2578215A induces a dose-dependent inhibition of Ser910 and Ser935 phosphorylation in both wild-type LRRK2 and LRRK2[G2019S] stably transfected into HEK293 cells. Synonyms: GSK2578215A; GSK-2578215A; GSK 2578215A. Grade: >98%. CAS No. 1285515-21-0. Molecular formula: C24H18FN3O2. Mole weight: 399.42. | |
| GSK2578215A | GSK2578215A is a potent and highly selective LRRK2 inhibitor, which exhibits IC 50 s of around 10 nM against both wild-type LRRK2 and the G2019S mutant. Uses: Scientific research. Group: Signaling pathways. CAS No. 1285515-21-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13237. | |
| GSK2578999A | GSK2578999A is a potent HIV-1 maturation inhibitor with IC50 values of 17 nM, 23 nM, 25 nM, and 8 nM for wild type, Q369H, V370A, and T371A respectively. Synonyms: GSK-8999; (3β)-3-(3-carboxy-3-methyl-1-oxobutoxy)-N-[1-(4-chlorophenyl)cyclopropyl]-α,21-dioxo-28-norlup-18-ene-17-acetamide. CAS No. 1422355-59-6. Molecular formula: C46H62ClNO7. Mole weight: 776.4. | |
| GSK2593074A | GSK2593074A is a necroptosis inhibitor for dual-targeting to both RIP1 and RIP3. Synonyms: GSK'074; 7-(1-methyl-1H-pyrazol-4-yl)-3-[1-(phenylacetyl)-2,3-dihydro-1H-indol-5-yl]thieno[3,2-c]pyridin-4-amine. Grade: 99%. CAS No. 1337531-06-2. Molecular formula: C27H23N5OS. Mole weight: 465.57. | |
| GSK2606414 | GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC50 of 0.4 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1337531-36-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18072. | |
| GSK 2606414 | GSK 2606414 is a potent and selective PERK inhibitor that suppresses PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small-molecule inhibitors. Synonyms: GSK2606414; GSK-2606414; GSK 2606414; GSK PERK Inhibitor. 1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone. Grade: 98%. CAS No. 1337531-36-8. Molecular formula: C24H20F3N5O. Mole weight: 451.453. | |
| GSK 2606414 | GSK 2606414. Group: Biochemicals. Alternative Names: 7-Methyl-5-[1-[[3- (trifluoromethyl) phenyl]acetyl]-2, 3-dihydro-1H-indol-5-yl]-7H-pyrrolo[2, 3-d]pyrimidin-4-amine. Grades: Highly Purified. CAS No. 1337531-36-8. Pack Sizes: 1mg. Molecular Formula: C24H22F3N5O, Molecular Weight: 453.46. US Biological Life Sciences. | Worldwide |
| GSK2636771 | GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a K i of 0.89 nM and an IC 50 of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms. Uses: Scientific research. Group: Signaling pathways. CAS No. 1372540-25-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15245. | |
| GSK2636771 | GSK2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. Uses: Antineoplastic agents. Synonyms: GSK2636771; GSK-2636771; GSK 2636771. CAS No. 1372540-25-4. Molecular formula: C22H22F3N3O3. Mole weight: 433.431. | |
| GSK 2636771 dihydrochloride | GSK 2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK 2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. Synonyms: GSK-2636771 dihydrochloride; GSK2636771 dihydrochloride; 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid dihydrochloride. Grade: 99%. CAS No. 2108806-07-9. Molecular formula: C22H22F3N3O3.2HCl. Mole weight: 506.35. | |
| GSK 264220A | GSK 264220A is an endothelial lipase and lipoprotein lipase inhibitor (IC50 = 0.13 and 0.10 μM, respectively). Inhibition of endothelial lipase may lead to an increase in HDL levels and GSK 264220A is expected to be a therapy for cardiovascular disease. Uses: Potential treatment of cardiovascular disease. Synonyms: GSK-264220A; GSK 264220A; GSK264220A. N-[2-Methyl-5-(1-piperidinylsulfonyl)-3-furanyl]-N'-phenylurea; 3-[2-methyl-5-(piperidine-1-sulfonyl)furan-3-yl]-1-phenylurea; 1-(2-methyl-5-piperidin-1-ylsulfonylfuran-3-yl)-3-phenylurea. Grade: ≥98% by HPLC. CAS No. 685506-42-7. Molecular formula: C17H21N3O4S. Mole weight: 363.43. | |
| GSK 264220A | GSK 264220A. Group: Biochemicals. Grades: Purified. CAS No. 685506-42-7. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK2643943A | GSK2643943A is a deubiquitylating enzyme (DUB) inhibitor with IC50 of 160 nM for USP20/Ub-Rho. Synonyms: GSK 2643943A; GSK-2643943A. CAS No. 2449301-27-1. Molecular formula: C17H12FN3. Mole weight: 277.30. | |
| GSK2643943A | GSK2643943A is a deubiquitinating enzyme (DUB) inhibitor targeting USP20. GSK2643943A has affinity with an IC50 of 160 nM for USP20/Ub-Rho. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC) [1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2449301-27-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111458. | |
| GSK2656157 | GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1337532-29-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13820. | |
| GSK2656157 | GSK2656157 is an ATP-competitive inhibitor of PERK enzyme activity with an IC50 of 0.9 nM. It is highly selective for PERK with IC50 values >100 nM against a panel of 300 kinases. GSK2656157 inhibits PERK activity in cells with an IC50 in the range of 10-30 nM as shown by inhibition of stress-induced PERK autophosphorylation, eIF2α substrate phosphorylation, together with corresponding decreases in ATF4 and CHOP proteins in multiple cell lines. Oral administration of GSK2656157 to mice shows a dose- and time-dependent pharmacodynamic response in pancreas as measured by PERK auto-phosphorylation. Twice daily dosing of GSK2656157 results in dose dependent inhibition of multiple human tumor xenografts growth in mice. Altered amino acid metabolism, decreased blood vessel density and vascular perfusion are potential mechanisms for the observed anti-tumor effect. However, despite its anti-tumor activity, given the on-target pharmacological effects of PERK inhibition on pancreatic function, development of any PERK inhibitor in human subjects would need to be cautiously pursued in cancer patients. Synonyms: GSK2656157; GSK 2656157; GSK-2656157. Grade: 0.98. CAS No. 1337532-29-2. Molecular formula: C23H21FN6O. Mole weight: 416.46. | |
| GSK 269962 | GSK 269962 is a potent ROCK inhibitor with IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively, which displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. It may be used in OAB treatment. It has been shown to block the generation of inflammatory cytokines in lipopolysaccharide-stimulated monocytes and to induce vasorelaxation in preconstricted rat aorta (IC50 = 35 nM). It lowers blood pressure in a rat model of hypertension. It induced a reduction in blood pressure of approximately 10, 20, and 50 mm Hg at doses of 1, 3, and 30 mg/kg. It represent a novel class of ROCK inhibitors that have profound effects in the vasculature, which may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases. Uses: Gsk 269962 may be used in oab treatment. it represent a novel class of rock inhibitors. Synonyms: GSK269962A; N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide; Aminofurazanyl-azabenzimidazole 6n; N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide. Grade: >99 %. CAS No. 850664-21-0. Molecular formula: C29H30N8O5. Mole weight: 570.60. | |
| GSK269962A | GSK269962A (GSK 269962) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A has anti-inflammatory and vasodilatory activities[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK 269962. CAS No. 850664-21-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15556. | |
| GSK269962A HCl | GSK269962 is a selective inhibitor of ROCK (Rho-associated protein kinase) with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively. GSK269962 displays > 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Synonyms: GSK269962B; GSK269962; GSK 269962. Molecular formula: C29H30N8O5·HCl. Mole weight: 607.06. | |
| GSK269962A hydrochloride | GSK269962A hydrochloride is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities. Synonyms: GSK269962 HCl; GSK 269962 hydrochloride. CAS No. 2095432-71-4. Molecular formula: C29H31ClN8O5. Mole weight: 607.06. | |
| GSK-269984A | GSK-269984A is a Prostaglandin E2 Receptor 1 antagonist with a pIC50 of 8.1. Synonyms: 2-Pyridinecarboxylic acid, 6-((5-chloro-2-((4-chloro-2-fluorophenyl)methoxy)phenyl)methyl)-, sodium salt. Grade: 95%. CAS No. 892664-04-9. Molecular formula: C20H13Cl2FNNaO3. Mole weight: 428.22. | |
| GSK-270822A | GSK-270822A is a G protein-coupled receptor kinases(GRK2) inhibitor, which has been directly implicated in the progression of heart failure. It would be used as useful chemical probes and leads for therapeutic applications ranging from heart failure to Parkinson's disease. Uses: Gsk-270822a would be used as useful chemical probes and leads for therapeutic applications ranging from heart failure to parkinson's disease. Synonyms: GSK270822A; GSK 270822A; N-(1H-indazol-5-yl)-2-methyl-4-(naphthalen-2-yl)-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxamide; NSC-756163. Grade: 98%. CAS No. 864082-23-5. Molecular formula: C24H20N4O2. Mole weight: 396.45. | |
| GSK2795039 | GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) with pIC50 of 6. GSK2795039 inhibited both the formation of ROS and the utilization of the enzyme substrates, NADPH and oxygen, in a variety of semirecombinant cell-free and cell-based NOX2 assays. Synonyms: GSK-2795039; GSK 2795039. CAS No. 1415925-18-6. Molecular formula: C23H26N6O2S. Mole weight: 450.56. | |
| GSK2795039 | GSK2795039 is a NADPH oxidase 2 (NOX2) inhibitor with a mean pIC50 of 6 in different cell-free assays. GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption[1].GSK2795039 reduces apoptosis[2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1415925-18-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 100 mg. Product ID: HY-18950. | |
| GSK2798745 | GSK2798745 is a potent, selective, and orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC50s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 can be used in cardiac and respiratory diseases research[1][2][3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1419609-94-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-19765. | |
| GSK2801 | GSK2801 is a potent, selective, orally active and cell active acetyl-lysine competitive BAZ2A and BAZ2B bromodomains inhibitor with Kd values of 136 nM and 257 nM, respectively. GSK2801 shows >50-fold selectivity for BAZ2A/B over BRD4[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1619994-68-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15658. | |
| GSK2801 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK2801 | GSK2801 is a A Selective Chemical Probe for BAZ2B/A bromodomains. BAZ2A/B belong to a family of ubiquitously expressed bromodomain containing proteins.probes/GSK2801). Synonyms: GSK2801; GSK-2801; GSK 2801. Grade: 98%. CAS No. 1619994-68-1. Molecular formula: C20H21NO4S. Mole weight: 371.45. | |
| GSK2807 Trifluoroacetate | GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive SMYD3 inhibitor, with a Ki of 14 nM and an IC50 of 130 nM. Synonyms: (S)-2-Amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(3-(dimethylamino)propyl)amino)butanoic acid 2,2,2-trifluoroacetic acid; 5'-{[(3S)-3-Amino-3-carboxypropyl][3-(dimethylamino)propyl]amino}-5'-deoxyadenosine trifluoroacetate (1:1); Acetic acid, 2,2,2-trifluoro-, compd. with adenosine, 5'-[[(3S)-3-amino-3-carboxypropyl][3-(dimethylamino)propyl]amino]-5'-deoxy- (1:1). Grade: ≥95%. CAS No. 2245255-66-5. Molecular formula: C21H33F3N8O7. Mole weight: 566.53. | |
| GSK2807 Trifluoroacetate | GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3 , with a K i of 14 nM and an IC 50 of 130 nM [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2245255-66-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-104009A. | |
| GSK-2818713 | GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex inhibitor, GSK-2818713 exhibited picomolar potency on genotype 1 variants. Uses: The treatment of hepatitis c. Synonyms: GSK-2818713; GSK2818713; GSK 2818713. | |
| GSK2830371 | GSK2830371 is an orally active, allosteric Wip1 phosphatase inhibitor with IC50 of 6 nM. Synonyms: GSK 2830371; GSK2830371; GSK-2830371. Grade: >98%. CAS No. 1404456-53-6. Molecular formula: C23H29ClN4O2S. Mole weight: 461.02. | |
| GSK2830371 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK 2830371 | GSK 2830371 is a highly selective Wip1 phosphatase inhibitor with IC50 of 6 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1404456-53-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-15832. | |
| GSK2837808A | GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1445879-21-9. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100681. | |
| GSK2837808A | GSK2837808A is a potent and specific lactate dehydrogenase A (LDHA) with IC50 values of 1.9 and 14 nM for LDHA and LDHB, respectively and inhibits lactate production in selected cancer cell lines. Synonyms: GSK2837808A; GSK-2837808A; GSK 2837808A; GSK2837808; GSK-2837808; GSK 2837808. 3-[[3-(cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl]amino]-5-(3,5-difluorophenoxy)benzoic acid. CAS No. 1445879-21-9. Molecular formula: C31H25F2N5O7S. Mole weight: 649.62. | |
| GSK2838232 | GSK2838232, a derivative of Betulin, is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection. Uses: Anti-hiv agents. Synonyms: GSK2838232; GSK-2838232; GSK 2838232; 4-[[(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-[(1R)-2-[(4-chlorophenyl)methyl-[2-(dimethylamino)ethyl]amino]-1-hydroxyethyl]-5a,5b,8,8,11a-pentamethyl-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dime. Grade: 99.34%. CAS No. 1443460-91-0. Molecular formula: C48H73ClN2O6. Mole weight: 809.56. | |
| GSK2850163 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK2850163 hydrochloride | GSK2850163 hydrochloride, an inositol-requiring enzyme-1 alpha (IRE1α) inhibitor, can inhibit IRE1α kinase activity and RNase activity with IC50s of 20 and 200 nM, respectively. Synonyms: 2,7-Diazaspiro[4.5]decane-7-carboxamide, 2-[(3,4-dichlorophenyl)methyl]-N-[(4-methylphenyl)methyl]-, hydrochloride (1:1), (5R)-; (5R)-2-(3,4-Dichlorobenzyl)-N-(4-methylbenzyl)-2,7-diazaspiro[4.5]decane-7-carboxamide hydrochloride (1:1). CAS No. 2319838-09-8. Molecular formula: C24H30Cl3N3O. Mole weight: 482.87. | |
| GSK2879552 | GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. It was just planed a Phase I/II trail by GSK against Myelodysplastic syndromes. Uses: Gsk2879552 has been found to be a lsd1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. Synonyms: GSK2879552; UNII-GT77Z6Y09Z; GSK-2879552; GSK 2879552; GT77Z6Y09Z; 1401966-69-5; 4-((4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid. Grade: 98%. CAS No. 1401966-69-5. Molecular formula: C23H28N2O2. Mole weight: 364.48. | |
| GSK2879552 | GSK2879552 an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/ KDM1A), with potential antineoplastic activity[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1401966-69-5. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18632. | |
| GSK2879552 | GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, GSK2879552 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the dimethylated form of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK2879552; GSK-2879552; GSK 2879552. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1401966-69-5. Molecular formula: C23H28N2O2. Mole weight: 364.48. Purity: >98%. IUPACName: 4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid. Canonical SMILES: O=C(O)C1=CC=C(CN2CCC(CN[C@H]3[C@H](C4=CC=CC=C4)C3)CC2)C=C1. Product ID: ACM1401966695. Alfa Chemistry ISO 9001:2015 Certified. |  |
| GSK2879552 dihydrochloride | GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1902123-72-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18632A. | |
| GSK2879552 dihydrochloride | GSK2879552 dihydrochloride, a selective, irreversible and orally active lysine specific demethylase 1 (LSD1/KDM1A) inhibitor, has potential antineoplastic activity. Synonyms: Benzoic acid, 4-[[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]-1-piperidinyl]methyl]-, hydrochloride (1:2); 4-{[4-({[(1R,2S)-2-Phenylcyclopropyl]amino}methyl)-1-piperidinyl]methyl}benzoic acid dihydrochloride. Grade: ≥95%. CAS No. 1902123-72-1. Molecular formula: C23H30Cl2N2O2. Mole weight: 437.40. | |
| GSK-2881078 | GSK-2881078, an indole derivative, has been found to be an androgen receptor modulator that could probably be effective against Cachexia. It is still under Phase I trail. Uses: Anabolic agents. Synonyms: GSK 2881078; GSK2881078; CS-5736; (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile. Grade: 98%. CAS No. 1539314-06-1. Molecular formula: C14H13F3N2O2S. Mole weight: 330.33. | |
| GSK-2894631A | GSK2894631A is an inhibitor of hematopoietic PGD synthase (HPGDS). Synonyms: HPGDS inhibitor 2. CAS No. 2101626-26-8. Molecular formula: C20H24F2N2O3. Mole weight: 378.4. | |
| GSK2982772 | GSK2982772, with potential effect to treat inflammatory diseases, potently binds to RIP1 with exquisite kinase specificity. In phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. Synonyms: GSK2982772; GSK 2982772; GSK-2982772; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide. CAS No. 1622848-92-3. Molecular formula: C20H19N5O3. Mole weight: 377.4. | |
Our database is helping our users find suppliers everyday.
